Used in pharmaceutical research as a potent and selective inhibitor of anaplastic lymphoma kinase (ALK). It demonstrates high efficacy in targeting ALK-positive non-small cell lung cancer (NSCLC) by blocking abnormal signaling pathways that drive tumor growth. The compound shows strong central nervous system penetration, making it valuable in treating brain metastases associated with ALK-positive cancers. It is also active against various resistant ALK mutations, including the common gatekeeper mutation, which enhances its utility in patients who have relapsed on earlier generation ALK inhibitors. Its pharmacokinetic profile supports once-daily dosing in clinical settings, contributing to its development as a therapeutic agent in oncology.